Equivalent, An innovator of patient engagement and health relationship management solutions, she applauds health systems participating in a recent initiative by the American Hospital Association, the Joint Commission, and Brigham and Women’s Hospital. The initiative is called: Promoting equity through a network of quality and safety peersThe new peer-to-peer network is focused on “improving health equity and reducing health disparities in the structural DNA of hospital operations and health system delivery,” said Dr. Gerald Harmon, president of the American Medical Association.
“Health inequalities are all too common. We must focus more fully on availability and access,” said Nir Altman, CEO of Equiva. “Digital solutions must be less complex and expensive — so they can be more widely adopted and work for all, regardless of race, ethnicity, age, disability, socioeconomic status, etc.”
Altman added that Equiva’s mission is rooted in health equity and supported by everyone within the organization.
It reads: “Humanity is better served when everyone is connected to individuals, information and experiences that support overall well-being. Patients, loved ones and healthcare professionals deserve a fairer and less fragmented Systems in which transformative technologies generate powerful intelligence that facilitates targeted care and health. This is the future we seek for all, and we can’t think of a more exciting goal.”
PrecisionGx The Series A financing has been completed, led by FCA Venture Partners, with participation from Commerce Ventures.
Its AI-enabled claims auditing technology creates automated claims intelligence that can be deployed early in the payment workflow, including prepayment and pre-adjudication positions, to prevent overpayments from occurring. Early customers include some of the largest U.S. health insurance and pharmaceutical companies, representing billions of patient events and more than $250 billion in claims in 2021.
“With this funding round, we are excited to invest in a broader and earlier financial impact for payers and pharma partners, including medical, prescription, discount and rebate payments. Ultimately, if we want to make it more affordable for patients When it comes to healthcare, we have to address inaccurate payments. The only way to do this at the scale we need is to use automated intelligence that can run within existing payment workflows,” said PrecisionGx CEO and Co-Founder Kasey Sousa said.
To read more information, Click here.
Jasper Health An agreement has been reached with Walgreens to provide the startup’s cancer care services through the Walgreens Find Care platform.
“There have been significant advances in oncology treatments and medicines in recent years, but there is still a need to provide a better cancer care experience for all,” said Greg Orr, chief commercial officer and general manager of Jasper Health. “By partnering with Walgreens to expand access to our cancer care services, we hope to help more people cope with the complexities of our healthcare system, ease their suffering, and improve their quality of life.”
Jasper Health recently introduced Coach+ services into its offerings to provide additional support for members’ mental health, sleep, nutrition, physical activity and financial needs.
To read more information, Click here.
Wavemaker Thirty Sixty Health, a venture fund focused on early-stage (mostly seed) healthcare disruptors and innovators, closed Fund II with $64 million, well above its first fund. Fund II’s limited partners include more than 300 healthcare organizations, healthcare executives across the United States, and a number of international investors.
Fund II aims to invest in 40-50 early-stage companies – mostly in the US, but some are allocated to non-US companies. Fund II has made multiple investments in some of the most high-profile healthcare startups in health tech, digital health, medical devices, telemedicine, artificial intelligence, pharma tech, science and markets.
To read more information, Click here.
Anagenex is a drug discovery company that combines large-scale data generation with machine learning to discover the next generation of small molecule drugs. It closed a $30 million Series A round led by Catalio Capital Management with participation from existing investors Lux Capital, Khosla Ventures, Obvious Ventures, Air Street Capital and Menlo Ventures. Catalio Capital Management will also receive board seats and observer roles.
“Traditional small-molecule drugs, which account for the majority of FDA approvals, remain the best and most cost-effective drugs for most patients,” said Nicolas Tilmans, CEO of Anagex. “However, their development remains very promising. Challenging. At Anagex, we build an evolution-inspired closed-loop iterative system that alternates between large-scale laboratory experiments and next-generation machine learning-driven predictions so that we can deliver novel small molecules to patients faster drug.”
To read more information, Click here.
picture: Arkindo, Getty Images
